Sarepta Therapeutics (MEX:SRPT) Tax Provision: MXN771 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:SRPT Sarepta Therapeutics Inc MEX:SRPT
35 GF Score
Price MXN294.00
GF Value MXN2,564.50
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Sarepta Therapeutics Tax Provision?

Sarepta Therapeutics MEX:SRPT 35 Tax Provision is MXN771 Mil as of Mar. 2026. GuruFocus rates MEX:SRPT with a GF Score™ of 35/100 and a GF Value™ of MXN2,564.50 (Possible Value Trap). The stock has 5 warning signs investors should review.

Sarepta Therapeutics's tax provision for the three months ended in Mar. 2026 was MXN-220 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was MXN771 Mil.

Sarepta Therapeutics Tax Provision Historical Data

* Premium members only.

The historical data trend for Sarepta Therapeutics's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics Tax Provision Chart

Sarepta Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.45 -263.68 -269.53 -532.55 -201.39

Sarepta Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,309.12 814.44 258.69 -81.94 -220.27
MEX:SRPT
35GF Score
Sarepta Therapeutics Inc MEX:SRPT
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sarepta Therapeutics Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN771 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of MXN771 Mil mean?
Sarepta Therapeutics (MEX:SRPT) has a Tax Provision of MXN771 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Sarepta Therapeutics and its competitors.
Is Sarepta Therapeutics' Tax Provision too high?
Sarepta Therapeutics' current Tax Provision is MXN771 Mil. Overall, Sarepta Therapeutics has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Tax Provision compare to MPLT and ZYME?
Sarepta Therapeutics' Tax Provision of MXN771 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Tax Provision is MXN771 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,564.50, compared to a current price of MXN294.00 — trading 88.5% below its estimated fair value. The current Tax Provision is MXN771 Mil. Sarepta Therapeutics' overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current Tax Provision is MXN771 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?

Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued. The current stock price of MXN294.00 is trading 88.5% below its estimated GF Value™ of MXN2,564.50. GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.

Key valuation signals for MEX:SRPT:

  • Tax Provision: MXN771 Mil
  • GF Value™: MXN2,564.50 vs. price of MXN294.00 (88.5% below fair value)
  • GF Score™: 35/100 with 5 warning signs

No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sarepta Therapeutics Business Description

Address 215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
35GF Score

Get the complete analysis for MEX:SRPT

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN294.00
Price
MXN2,564.50
GF Value